公开(公告)号：WO2011059839A1

公开(公告)日：2011-05-19

申请号：PCT/US2010/054880

申请日：2010-10-29

Applicant: SIRTRIS PHARMACEUTICALS, INC. ,  NG, Pui, Yee ,  BLUM, Charles ,  MCPHERSON, Lauren ,  PERNI, Robert, B. ,  VU, Chi, B. ,  AHMED, Mohammed, Mahmood ,  DISCH, Jeremy, S.

Inventor： NG, Pui, Yee ,  BLUM, Charles ,  MCPHERSON, Lauren ,  PERNI, Robert, B. ,  VU, Chi, B. ,  AHMED, Mohammed, Mahmood ,  DISCH, Jeremy, S.

IPC: C07D471/04 ,  C07D487/04 ,  C07D519/00 ,  A61K31/4985 ,  A61K31/5365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/553 ,  A61K31/551 ,  A61K31/55 ,  A61P5/50

CPC classification number: C07D498/04 ,  C07D471/04

Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract translation: 本文提供了新的沉默调节蛋白的调节化合物及其使用方法。 沉默调节蛋白的调节化合物可用于增加细胞的寿命，以及治疗和/或预防各种各样的疾病和病症，包括例如与老化或紧张相关的疾病或病症，糖尿病，肥胖症，神经变性疾病， 心血管疾病，血液凝固障碍，炎症，癌症和/或潮红以及将受益于增加的线粒体活性的疾病或病症。 还提供了包含与另一种治疗剂组合的沉默调节蛋白的调节化合物的组合物。

公开(公告)号：WO2009089011A8

公开(公告)日：2010-08-26

申请号：PCT/US2009000078

申请日：2009-01-07

Applicant: SIRTRIS PHARMACEUTICALS INC ,  LUNSMANN WALTER JOSEPH ,  ELLIOTT PETER ,  LAMBERT PHILIP

Inventor： LUNSMANN WALTER JOSEPH ,  ELLIOTT PETER ,  LAMBERT PHILIP

IPC: A61K9/08 ,  A61K9/107 ,  A61K31/05

CPC classification number: A61K9/08 ,  A61K9/107 ,  A61K31/05

Abstract: Resveratrol can be used to treat or inhibit the onset of many diseases that are related to the aging process, but large doses are required. The present invention provides concentrated liquid formulations of resveratrol, typically having a resveratrol concentration of at least 10% by weight. These formulations improve patient compliance because the patient need not consume such a large volume of a resveratrol formulation.

Abstract translation: 白藜芦醇可用于治疗或抑制与衰老过程相关的许多疾病的发病，但需要大剂量。 本发明提供白藜芦醇的浓缩液体制剂，其通常具有至少10重量％的白藜芦醇浓度。 这些制剂改善了患者的依从性，因为患者不需要消耗如此大量的白藜芦醇制剂。

公开(公告)号：WO2008156869A2

公开(公告)日：2008-12-24

申请号：PCT/US2008/007776

申请日：2008-06-20

Applicant: SIRTRIS PHARMACEUTICALS, INC. ,  BEMIS, Jean ,  DISCH, Jeremy, S. ,  NG, Pui, Yee ,  OALMANN, Christopher ,  PERNI, Robert, B. ,  VU, Chi, B.

Inventor： BEMIS, Jean ,  DISCH, Jeremy, S. ,  NG, Pui, Yee ,  OALMANN, Christopher ,  PERNI, Robert, B. ,  VU, Chi, B.

IPC: C07D513/04 ,  A61K31/437 ,  A61P3/10

CPC classification number: C07D513/04

Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.

Abstract translation: 本文提供了新的沉默调节蛋白的调节化合物及其使用方法。 沉默调节蛋白的调节化合物可用于增加细胞的寿命，以及治疗和/或预防各种各样的疾病和病症，包括例如与老化或紧张相关的疾病或病症，糖尿病，肥胖症，神经变性疾病， 心血管疾病，血液凝固障碍，炎症，癌症和/或潮红以及将受益于增加的线粒体活性的疾病或病症。 还提供了包含沉默调节蛋白的调节性化合物与另一种治疗剂组合的组合物。

公开(公告)号：WO2006127987A3

公开(公告)日：2008-04-17

申请号：PCT/US2006020406

申请日：2006-05-24

Applicant: SIRTRIS PHARMACEUTICALS INC ,  MILBURN MICHAEL ,  WESTPHAL CHRISTOPH H ,  LIVINGSTON DAVID J ,  LAMBERT PHILIP ,  NORMINGTON KARL D ,  ELLIOTT PETER

Inventor： MILBURN MICHAEL ,  WESTPHAL CHRISTOPH H ,  LIVINGSTON DAVID J ,  LAMBERT PHILIP ,  NORMINGTON KARL D ,  ELLIOTT PETER

IPC: A61K31/05 ,  A61K31/353 ,  A61P27/06

CPC classification number: A61K31/05 ,  A61K31/353

Abstract: Sirtuin modulators, particularly sirtuin activators, are useful in treating vision impairment. In general, the sirtuin modulators inhibit the progression of vision impairment resulting from various eye disorders. The invention also includes pharmaceutically acceptable formulations of sirtuin modulators, particular ophthalmically acceptable formulations.

Abstract translation: Sirtuin调节剂，特别是sirtuin激活剂，可用于治疗视力障碍。 通常，沉默调节蛋白调节剂抑制由各种眼睛疾病引起的视力障碍的进展。 本发明还包括Sirtuin调节剂的药学上可接受的制剂，特别是眼用可接受的制剂。

公开(公告)号：WO2006078941A3

公开(公告)日：2007-02-22

申请号：PCT/US2006002092

申请日：2006-01-20

Applicant: SIRTRIS PHARMACEUTICALS INC ,  MILBURN MICHAEL ,  ECKSTEIN JENS W

Inventor： MILBURN MICHAEL ,  ECKSTEIN JENS W

IPC: C07D403/04 ,  A61K31/4025 ,  A61P3/10

CPC classification number: C07D403/04

Abstract: Provided herein are novel sirtuin-activating compounds and methods of use thereof. The sirtuin-activating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-activating compound in combination with another therapeutic agent.

Abstract translation: 本文提供了新的沉默调节蛋白激活化合物及其使用方法。 沉默调节蛋白激活化合物可用于增加细胞的寿命，以及治疗和/或预防多种疾病和病症，包括例如与老化或紧张相关的疾病或病症，糖尿病，肥胖症，神经变性疾病， 心血管疾病，凝血障碍，炎症，癌症和/或潮红。 还提供了包含与另一种治疗剂组合的沉默调节蛋白激活化合物的组合物。

公开(公告)号：WO2007019345A1

公开(公告)日：2007-02-15

申请号：PCT/US2006/030511

申请日：2006-08-04

Applicant: SIRTRIS PHARMACEUTICALS, INC. ,  NUNES, Joseph, J. ,  MILNE, Jill ,  BEMIS, Jean ,  XIE, Roger ,  VU, Chi, B. ,  NG, Pui, Yee ,  DISCH, Jeremy, S.

Inventor： NUNES, Joseph, J. ,  MILNE, Jill ,  BEMIS, Jean ,  XIE, Roger ,  VU, Chi, B. ,  NG, Pui, Yee ,  DISCH, Jeremy, S.

IPC: C07D471/04 ,  A61K31/435 ,  A61P3/00 ,  A61P25/00 ,  A61P27/00 ,  A61P39/00 ,  A61P7/00 ,  A61P21/00

CPC classification number: C07D235/18 ,  C07D401/12 ,  C07D403/12 ,  C07D513/04

Abstract: Provided herein are imidazopyridine derivatives of formulas ((XIV), (XV),(XVI) and (XVII) which are sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract translation: 本文提供了作为沉默调节蛋白的调节性化合物的式（（XIV），（XV），（XVI）和（XVII））的咪唑并吡啶衍生物及其使用方法。沉默调节蛋白的调节化合物可用于增加细胞的寿命 ，以及治疗和/或预防各种各样的疾病和病症，包括例如与老化或紧张相关的疾病或病症，糖尿病，肥胖症，神经变性疾病，心血管疾病，血液凝固病症，炎症，癌症和/或潮红 以及由于增加的线粒体活性而有益的疾病或病症。还提供了包含沉默调节蛋白的调节化合物与另一种治疗剂组合的组合物。

公开(公告)号：WO2006094248A1

公开(公告)日：2006-09-08

申请号：PCT/US2006/007778

申请日：2006-03-03

Applicant: SIRTRIS PHARMACEUTICALS, INC. ,  MILBURN, Michael ,  MILNE, Jill ,  NORMINGTON, Karl, D.

Inventor： MILBURN, Michael ,  MILNE, Jill ,  NORMINGTON, Karl, D.

IPC: C07D207/16 ,  C07D409/04 ,  C07D409/14 ,  C07D487/04 ,  A61K31/401 ,  A61K31/4025 ,  A61P9/00

CPC classification number: C07D487/04 ,  C07D207/16 ,  C07D409/04 ,  C07D409/14

Abstract: ABSTRACT Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract translation: 摘要本文提供了新型沉默调节蛋白的调节化合物及其使用方法。 沉默调节蛋白的调节化合物可用于增加细胞的寿命，以及治疗和/或预防各种各样的疾病和病症，包括例如与老化或紧张相关的疾病或病症，糖尿病，肥胖症，神经变性疾病， 心血管疾病，凝血障碍，炎症，癌症和/或潮红以及由线粒体活性增加所致的疾病或病症。 还提供了包含与另一种治疗剂组合的沉默调节蛋白的调节化合物的组合物。

公开(公告)号：WO2006094236A1

公开(公告)日：2006-09-08

申请号：PCT/US2006/007745

申请日：2006-03-03

Applicant: SIRTRIS PHARMACEUTICALS, INC. ,  MILBURN, Michael ,  MILNE, Jill ,  BEMIS, Jean ,  NUNES, Joseph, J. ,  XIE, Roger ,  NORMINGTON, Karl, D. ,  VU, Chi, B.

Inventor： MILBURN, Michael ,  MILNE, Jill ,  BEMIS, Jean ,  NUNES, Joseph, J. ,  XIE, Roger ,  NORMINGTON, Karl, D. ,  VU, Chi, B.

IPC: C07D498/04 ,  C07D513/04 ,  A61K31/435 ,  A61P3/00 ,  A61P7/00 ,  A61P21/00 ,  A61P25/00 ,  A61P27/00 ,  A61P35/00 ,  C07D241/42 ,  C07D235/18 ,  C07D263/56 ,  C07D277/66 ,  C07D265/22 ,  C07D471/04

CPC classification number: C07D277/66 ,  C07D235/18 ,  C07D241/42 ,  C07D263/57 ,  C07D265/22 ,  C07D471/04 ,  C07D513/04

Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treatin and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract translation: 本文提供了新的沉默调节蛋白的调节化合物及其使用方法。 沉默调节蛋白的调节化合物可用于增加细胞的寿命，并且治疗和/或预防各种各样的疾病和病症，包括例如与老化或紧张相关的疾病或病症，糖尿病，肥胖症，神经变性疾病， 心血管疾病，凝血障碍，炎症，癌症和/或潮红以及由线粒体活性增加所致的疾病或病症。 还提供了包含与另一种治疗剂组合的沉默调节蛋白的调节化合物的组合物。

公开(公告)号：WO2006079021A2

公开(公告)日：2006-07-27

申请号：PCT/US2006/002267

申请日：2006-01-20

Applicant: SIRTRIS PHARMACEUTICALS, INC. ,  SINCLAIR, David ,  MILBURN, Michael ,  LANGER, Robert, S. ,  WESTPHAL, Christoph, H.

Inventor： SINCLAIR, David ,  MILBURN, Michael ,  LANGER, Robert, S. ,  WESTPHAL, Christoph, H.

IPC: A61K31/00 ,  A61K31/05 ,  A61K31/352 ,  A61K31/122 ,  A61K45/06 ,  A61P3/04 ,  A61P15/12

CPC classification number: A61K45/06 ,  A61K31/00 ,  A61K31/05 ,  A61K31/122 ,  A61K31/137 ,  A61K31/352 ,  A61K31/353 ,  A61K31/426 ,  A61K31/44 ,  A61K31/445 ,  A61K31/551 ,  A61K31/56 ,  A61K31/57 ,  A61K31/7048 ,  A61K38/28 ,  A61K2300/00

Abstract: Provided herein are methods and compositions for treating and/or preventing flushing and/or weight gain. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary embodiments include methods and compositions for counteracting drug-induced weight gain and/or drug-induced flushing by administering a sirtuin-activating compound.

Abstract translation: 本文提供了用于治疗和/或预防潮红和/或体重增加的方法和组合物。 方法可以包括调节sirtuin的活性或水平，例如SIRT1或Sir2。 示例性实施方案包括通过施用沉默调节蛋白的活化化合物来抵消药物诱导的体重增加和/或药物诱发的潮红的方法和组合物。

公开(公告)号：WO2006078941A2

公开(公告)日：2006-07-27

申请号：PCT/US2006/002092

申请日：2006-01-20

Applicant: SIRTRIS PHARMACEUTICALS, INC. ,  MILBURN, Michael ,  ECKSTEIN, Jens, W.

Inventor： MILBURN, Michael ,  ECKSTEIN, Jens, W.

IPC: C07D403/04 ,  A61K31/4025 ,  A61P3/10

CPC classification number: C07D403/04

Abstract: Provided herein are novel sirtuin-activating compounds and methods of use thereof. The sirtuin-activating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-activating compound in combination with another therapeutic agent.

Abstract translation: 本文提供了新的沉默调节蛋白激活化合物及其使用方法。 沉默调节蛋白激活化合物可用于增加细胞的寿命，以及治疗和/或预防多种疾病和病症，包括例如与老化或紧张相关的疾病或病症，糖尿病，肥胖症，神经变性疾病， 心血管疾病，凝血障碍，炎症，癌症和/或潮红。 还提供了包含与另一种治疗剂组合的沉默调节蛋白激活化合物的组合物。